271 related articles for article (PubMed ID: 37758652)
1. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
2. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
3. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
Dillard P; Casey N; Pollmann S; Vernhoff P; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Oncoimmunology; 2021; 10(1):1936757. PubMed ID: 34235003
[TBL] [Abstract][Full Text] [Related]
4. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Front Immunol; 2019; 10():2766. PubMed ID: 31921104
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract][Full Text] [Related]
6. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
[TBL] [Abstract][Full Text] [Related]
7. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
8. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
9. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
10. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
12. In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
Willimsky G; Beier C; Immisch L; Papafotiou G; Scheuplein V; Goede A; Holzhütter HG; Blankenstein T; Kloetzel PM
Elife; 2021 Apr; 10():. PubMed ID: 33875134
[TBL] [Abstract][Full Text] [Related]
13. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
Reimann H; Nguyen A; Sanborn JZ; Vaske CJ; Benz SC; Niazi K; Rabizadeh S; Spilman P; Mackensen A; Ruebner M; Hein A; Beckmann MW; van der Meijden ED; Bausenwein J; Kretschmann S; Griffioen M; Schlom J; Gulley JL; Lee KL; Hamilton DH; Soon-Shiong P; Fasching PA; Kremer AN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172517
[TBL] [Abstract][Full Text] [Related]
15. Identification and affinity enhancement of T-cell receptor targeting a KRAS
Zhang M; Xu W; Luo L; Guan F; Wang X; Zhu P; Zhang J; Zhou X; Wang F; Ye S
Commun Biol; 2024 Apr; 7(1):512. PubMed ID: 38684865
[TBL] [Abstract][Full Text] [Related]
16. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza RA; Wu D; Pierce BG
Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.
Ebrahimi-Nik H; Michaux J; Corwin WL; Keller GL; Shcheglova T; Pak H; Coukos G; Baker BM; Mandoiu II; Bassani-Sternberg M; Srivastava PK
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219806
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic self-peptides - the great unknowns in autoimmunity: Identifying T-cell epitopes driving the autoimmune response in autoimmune diseases.
Prinz JC
Front Immunol; 2022; 13():1097871. PubMed ID: 36700227
[TBL] [Abstract][Full Text] [Related]
20. Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy.
Wilson EA; Anderson KS
Expert Rev Proteomics; 2018 Dec; 15(12):1065-1077. PubMed ID: 30408427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]